Trump’s Drug Pricing Plan: The Headlines Are The Goal – But Also A Threat
Executive Summary
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
You may also be interested in...
Rx Industry Reassessing Political Donations In Wake Of Riots; Shift Towards Democrats Already Underway
Donation patterns in 2020 campaign suggest rethinking may have taken place before the mob attacked the Capitol, potentially an assessment of the election prospects or because of Trump’s policies during his term.
Capitol Hill Riot Draws Manufacturing Group’s Call For Trump’s Removal
PhRMA and BIO are members of the National Association of Manufacturers, which made the statement urging the 25th amendment be invoked.
US Drug Pricing Reform Post-Election: Scenarios To Consider And Lessons Learned
Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.